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58 Objective: Examine the association between preeclampsia and attention deficit hyperactivity 
59 disorder (ADHD), using a large Swedish-based registry cohort.
60 Methods: This study comprised 2,047,619 children, with 114,934 (5.6%) cases of ADHD. 
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62 2.Preeclampsia and small for gestational age (SGA) combined. ADHD was determined in one of 
63 two ways: 1.If a diagnosis of ADHD was present in the National Patient Register or 2.If an 
64 individual was in receipt of ADHD medication in the Prescribed Drug Register. Multivariate Cox 
65 proportional hazards regression analysis allowed adjustment for several 
66 perinatal/sociodemographic factors. Sibling-matched analysis further controlled for shared genetic 
67 and familial confounding.
68 Results: In the adjusted Cox model, preeclampsia was associated with an increase in likelihood of 
69 ADHD (HR: 1.15, 95% CI: 1.12, 1.19). The HR for preeclampsia and those born SGA was 1.43 
70 (95% CI: 1.31, 1.55) in the adjusted model, compared to those unexposed to preeclampsia/SGA. 
71 The sibling-matched analysis did not materially change these associations (HR: 1.13, 95% CI: 
72 1.05, 1.22) and 1.55 (95% CI: 1.28, 1.88). 
73 Conclusions: Exposure to preeclampsia or preeclampsia/SGA was associated with ADHD, 
74 independent of genetic/familial factors shared by siblings. However, it is important to note that 
75 sibling-matched analysis can only adjust for factors that are constant between pregnancies, 
76 therefore residual confounding cannot be ruled out. Further research is needed to explore 
77 modifiable risk factors and identify those most-at-risk babies following delivery.
78




83  This population-based cohort study suggests that preeclampsia, as well as preeclampsia 
84 and small for gestational age (SGA) combined (i.e. SGA baby exposed to preeclampsia), 
85 are associated with an increase in the likelihood of ADHD, independent of genetic/familial 
86 factors shared by siblings.
87  Placental pathology may be a common mechanism increasing the likelihood of ADHD as a 
88 stronger association was observed for preeclampsia/SGA, rather than preeclampsia alone.
89  Further research is needed to explore modifiable risk factors and identify those most-at-risk 
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93  A lack of robust data on gestational hypertension limited the analysis to preeclampsia-
94 ADHD only; therefore, the comparison group may contain women with a diagnosis of 
95 gestational hypertension. However, a gestational hypertension-ADHD association would 
96 more likely bias our results towards the null.  
97  Outpatient data only started becoming available in 2001, meaning more severe cases of 
98 ADHD may have been overrepresented due to a reliance on inpatient data. However, 
99 restricting the study population to 2001-2010 did not have a large impact on findings. 
100  While sibling-matched analysis may have reduced confounding due to shared genetic and 
101 familial factors, the possibility of residual confounding cannot be ruled out in 
102 observational studies.
103
104 Data availability statement
105 Authors are not permitted to share data due to GDPR restrictions.
106 Introduction 
107 Preeclampsia, which affects approximately 5% of all pregnancies1, is one of the leading causes of 
108 maternal morbidity and mortality, and was recently redefined by the International Society for the 
109 Study of Hypertension in Pregnancy (ISSHP) as gestational hypertension accompanied by at least 
110 two of the following: proteinuria and/or other maternal organ dysfunction and/or uteroplacental 
111 dysfunction2. 
112 Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised 
113 by inattention, hyperactivity and impulsivity. ADHD has a global pooled prevalence of over 5%, 
114 and while this estimate varies significantly worldwide, the variability can mostly be explained by 
115 methodological differences between studies3, 4. Despite high heritability estimates, gene 
116 environment interactions may also play a role5.
117 Preeclampsia has been linked to adverse neurodevelopmental outcomes, including ADHD6, 7. 
118 Pooled results from a recent systematic review suggest that preeclampsia is associated with a 30% 
119 increase in odds of ADHD6. It is worth noting however, that while an apparent relationship exists 
120 in previous literature, residual confounding and quality of the studies may be a concern. For 
121 example, only one of ten studies included in the systematic review controlled for a combination of 
122 key potential confounders, such as maternal age, socioeconomic status, ethnicity, and maternal 
123 mental illness6, 8.
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125 The aim of this study was to examine the association between preeclampsia and ADHD using a 
126 large population-based cohort study, controlling for a wide range of potential confounding factors, 




131 Materials and Methods
132 Study Population
133 All singleton live births in Sweden from 1990 to 2010, with a follow-up until December 2016, 
134 were included in the study. Data were obtained from Swedish National Registers. These included 
135 the Medical Birth Register, National Patient Register, Prescribed Drug Register, Multi-generation 
136 Register, Total Population Register and Register of Education, linked using personal identification 
137 numbers assigned to Swedish residents9.
138 Ethical approval was previously obtained from the Stockholm Regional Ethical Review Board 




143 Data on preeclampsia was obtained from the Medical Birth Register which contains data on over 
144 97% of all births in Sweden10. We used two alternate definitions of preeclampsia:
145 1. Preeclampsia: Blood pressure ≥140/90 mmHg on or after 20 weeks’ gestation combined with 
146 proteinuria (≥0.3 g/day or ≥1 on a urine dipstick on at least two occasions). Preeclampsia was 
147 classified using the Swedish version of the ICD, Ninth and Tenth Revision11: ICD‐9 until 1996 
148 (codes 642E‐G) and ICD‐10 from 1997 (codes O14‐O15)12, 13.
149 2. Preeclampsia and small for gestational age (SGA) combined: We combined preeclampsia (as 
150 above) and SGA as a proxy for preeclampsia with placental dysfunction2. SGA was defined as 
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157 Data on ADHD were obtained from the National Patient Register and the Prescribed Drug 
158 Register. The National Patient Register was launched in 1964, contains inpatient psychiatric 
159 diagnoses from 1973, and outpatient data since 2001 (with increasingly better coverage until 
160 2006)15-17. The Prescribed Drug Register was expanded on 1st July 2005 to include personal 
161 identification numbers allowing linkage to other registers17, 18. 
162 A diagnosis of ADHD was determined in one of two ways: 
163 1. If a diagnosis of ADHD was present in the National Patient Register, using ICD-10 (code F90 
164 and F98.8), available since 199717. 
165 2. If the subject was in receipt of ADHD medication in the Prescribed Drug Register. ADHD 
166 medication data was classified according to Anatomical Therapeutic Chemical classification 
167 system, and included amphetamine (N06BA01), dexamphetamine (N06BA02), psychostimulants 
168 methyphenidate (N06BA04) and noradrenergic reuptake inhibitor atomoxetine (N06BA09).
169
170 Confounding Factors
171 Potential confounders were based on previous literature. Year of birth, infant sex, maternal age, 
172 parental country of birth, parity, maternal smoking status, body mass index (BMI) at first antenatal 
173 visit and gestational weight gain were obtained from the Medical Birth Register. Parental 
174 depression, bipolar disorder, and non-affective psychiatric disorders were obtained from the 
175 National Patient Register. Family income and parental level of education data were obtained from 
176 the Total Population Register and Register of Education. Information on all cofounders was 
177 available for the entire study period. Where a variable had missing data, the data were added as a 
178 separate category and included in the various Cox regression analyses by means of an indicator 




183 All data were analysed using Stata/MP 14.2. We conducted Cox proportional hazards regression 
184 analysis to calculate a hazard ratio (HR) and 95% confidence interval for a preeclampsia-ADHD 
185 relationship, preeclampsia/SGA-ADHD (i.e SGA baby exposed to preeclampsia) relationship and 
186 the relationship between preeclampsia without SGA and ADHD. 
187 Similar to a previous ADHD study conducted on this population (and because a diagnosis of 
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189 1st January 1997 for children who turned three years of age before 1997). Children continued to 
190 be followed up until he/she received a diagnosis of ADHD, prescription for ADHD, death, 
191 emigration, or the study period had ended (31st December 2016).
192 Partially adjusted models were stratified for year of birth in order to satisfy the proportional hazard 
193 assumption (model 1). Fully adjusted models (model 2) controlled for year of birth, infant sex, 
194 maternal age, parental country of birth, parity, parental depression, bipolar disorder, and non-
195 affective psychiatric disorder, family income, maternal smoking status, BMI at first antenatal visit, 
196 gestational weight gain and parental level of education.
197 Sibling-matched analysis: We conducted a sibling-matched analysis (model 3) to control for 
198 shared genetic and familial confounding, using stratified Cox regression. This analysis was 
199 matched on maternal ID and consisted of a separate stratum for each family in order to estimate 
200 the probability of ADHD within family20. We adjusted for the same potential confounders as 
201 model 2 with the exception of maternal country of birth as this is the same across sibling pairs. 
202 Finally, we repeated these analyses, firstly, including only those with both an ICD code for ADHD 
203 and if the subject was in receipt of ADHD medication, and secondly, including only those with an 
204 ICD code for ADHD.
205 Post-hoc analysis: We examined the association between SGA only and ADHD compared to non-
206 exposure to SGA/non-exposure to preeclampsia.
207 E-value: We calculated the E-value for the statistically significant primary effect estimates and 
208 lower limits of their 95% confidence interval (CI) to examine the extent of unmeasured 
209 confounding, using the publicly available online E-value calculator: 
210 (https://evalue.hmdc.harvard.edu/app/)21, 22. In summary, an E-value is a continuous measure that 
211 quantifies the minimum strength of association an unmeasured confounder would need to have 
212 with both preeclampsia and ADHD in order to explain away an effect estimate22.
213 Sensitivity analyses: We conducted several sensitivity analyses, decided a priori. For example, 
214 while classifying preeclampsia into mild/severe is not recommended in clinical practice because it 
215 is a complex disorder that can deteriorate rapidly, gestational age is sometimes used as a proxy for 
216 preeclampsia with severe features. As a result, preeclampsia could be considered severe if delivery 
217 occurred before 34 weeks’ gestation23. Therefore, we examined the association between 
218 preeclampsia and ADHD by gestational age. In addition, it is possible that a mother’s lifestyle 
219 factors could change between pregnancies. As a result, we excluded women who had preeclampsia 
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221 diagnosis of preeclampsia in subsequent pregnancies only. Additional sensitivity analyses 
222 included restricting the study population to 2001-2010 (when outpatient data on ADHD started to 
223 become available), and restricting the study population to 1994-2010 to ensure every child begins 
224 follow-up at their third birthday. Furthermore, we included ‘preeclampsia excluding chronic 
225 hypertension’ as the exposure, and ‘preeclampsia with chronic hypertension’ as the exposure. We 
226 examined preeclampsia-ADHD excluding those with a family history of mental illness. We 
227 analysed the relationship between preeclampsia with low/intermediate APGAR score at five 
228 minutes, while we also examined a preeclampsia-ADHD relationship by maternal age, in addition 
229 to preeclampsia-ADHD by BMI group at time of first antenatal visit. Finally, we investigated a 
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253 Results
254 Descriptive Statistics
255 A total of 2,142,694 live births were recorded in the Swedish Medical Birth Register between 
256 1990 and 2010. After excluding 61,172 multiple births, 30,636 children who were censored before 
257 their third birthday, and 3267 children who turned three years of age before 1997 but were 
258 censored before follow-up began on 1st January 1997, a total of 2,047,619 children remained in 
259 the final cohort (Table 1). 
260 There were 57,493 (2.8%) children exposed to preeclampsia and 7191 (0.4%) exposed to 
261 preeclampsia and SGA combined. There were 114,934 (5.6%) cases of ADHD. Of these 101,075 
262 (87.9%) cases were prescribed ADHD medication at some point, and 94,708 (82.4%) cases had an 
263 ICD diagnosis. A total of 80,849 (70.3%) cases were recorded with both an ICD code and 
264 medication, while there were 13,859 (12.1%) cases with an ICD code only, and 20,226 (17.6%) 
265 cases with medication only. 
266
267 Association between preeclampsia, preeclampsia/SGA and ADHD
268 In the fully adjusted model (model 2), the results suggested an association between preeclampsia 
269 and ADHD (HR: 1.15, 95% CI: 1.12, 1.19) compared to those unexposed to preeclampsia. Result 
270 of the sibling-matched analysis (model 3) did not significantly change (HR: 1.13, 95% CI: 1.05, 
271 1.22). The HR for those born SGA and exposed to preeclampsia was 1.43 (95% CI: 1.31, 1.55) in 
272 the adjusted model (model 2), and 1.55 (95% CI: 1.28, 1.88) in the sibling-match model (model 3), 
273 while the HR for those exposed to preeclampsia but not born SGA was 1.12 (95% CI: 1.08, 1.16) 
274 in model 2, and 1.09 (95% CI: 1.01, 1.18) in model 3. Limiting the data to those with both an ICD 
275 code and medication data did not materially change results, while including only those with an 
276 ICD code for ADHD produced similar results (Table 2). 
277 Post-Hoc Analysis
278 The adjusted HR for SGA only (i.e. SGA without preeclampsia) and ADHD was 1.32 (95% CI: 
279 1.27, 1.37), while the HR in the sibling-matched analysis was 1.29 (95% CI: 1.19, 1.39) compared 
280 to non-exposure to SGA/non-exposure to preeclampsia (Table 2).
281
282 E-Values
283 The E-values for significant primary effect estimates were 1.51 for preeclampsia, 2.47 for 
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285 corresponding lower limits of their 95% CI were 1.28, 1.88 and 1.11 respectively. (see eTable 1 in 
286 Supplement for worked example on preeclampsia-ADHD).
287
288 Sensitivity Analyses
289 Preeclampsia and ADHD by gestational age
290 When we restricted analysis to children born ≥39 weeks’ gestational age, the HR for a 
291 preeclampsia-ADHD relationship was 1.07 (95% CI: 1.02, 1.12). Among children born at 37-38 
292 weeks’, the HR in those exposed to preeclampsia was 1.20 (95% CI: 1.13, 1.28), while the HR 
293 among those not exposed to preeclampsia was 1.09 (95% CI: 1.08, 1.11), when compared to non-
294 exposure to preeclampsia in those born ≥39 weeks’ gestational age. Exposure to preeclampsia 
295 (among children born 34-36 weeks’) was associated with a 24% increase in likelihood of ADHD 
296 (HR: 1.24, 95% CI: 1.14, 1.35), while those unexposed to preeclampsia had a 14% increased 
297 likelihood of ADHD among those born at a similar gestational age (HR: 1.14, 95% CI: 1.11, 1.18). 
298 Finally, the HR among those exposed to preeclampsia (born <34 weeks’ gestational age) was 1.74 
299 (95% CI: 1.60, 1.91), while the HR among those not exposed to preeclampsia (born <34 weeks’ 
300 gestational age) was 1.49 (95% CI: 1.42, 1.96) when compared to non-exposure to preeclampsia 
301 among those born ≥39 weeks’ gestational age (Table 3). 
302
303 Additional sensitivity analyses
304 Results of additional sensitivity analyses are outlined in eResults and eTable 2 in the Supplement 
305 and were not materially different from the primary analysis. In sum, when we excluded women 
306 who had preeclampsia in their first pregnancy, the adjusted HR was 1.21. When we restricted the 
307 study population to 2001-2010 and 1994-2010, the HR was 1.21 and 1.14 respectively. The fully 
308 adjusted HR for preeclampsia (excluding chronic hypertension) and preeclampsia (with chronic 
309 hypertension) were 1.15 and 1.18 respectively. The HR for preeclampsia (excluding those with a 
310 family history of mental illness was 1.16. Preeclampsia (with low/intermediate APGAR at 5 
311 minutes) increased the likelihood of ADHD by 13% when compared to non-exposure to 
312 preeclampsia in those with a low/intermediate APGAR score. Results of the subgroup analysis 
313 suggested that preeclampsia was significantly associated with ADHD at each category of maternal 
314 age and at each category of BMI at first antenatal visit. The HR for preeclampsia-ADHD in males 
315 was 1.18 compared to non-exposure to preeclampsia in males, while the HR for preeclampsia-
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317 exposure to preeclampsia in males was associated with a 9% increase in likelihood of ADHD 








326 The aim of this study was to examine the association between preeclampsia and 
327 preeclampsia/SGA and ADHD, using a large population-based cohort study. We have yielded 
328 three principal findings. First, after controlling for known potential confounding factors, 
329 preeclampsia was associated with a 15% increase in likelihood of ADHD when compared to non-
330 exposure to preeclampsia. This finding was similar in the sibling-matched analysis suggesting that 
331 this apparent preeclampsia-ADHD relationship was not due to shared genetics or familial 
332 environment. This result is in line with the pooled estimate from a systematic review, which 
333 suggested that preeclampsia was associated with a 30% increase in odds of ADHD, with 
334 individual study estimates ranging from 1.19 to 1.506. 
335 Second, as SGA is associated with uteroplacental dysfunction24, and due to recent guidelines put 
336 forward by ISSHP to include uteroplacental dysfunction in the definition of preeclampsia, we 
337 combined preeclampsia and SGA into a single exposure as a crude proxy for preeclampsia with 
338 placental dysfunction. Being an SGA baby and exposed to preeclampsia was associated with a 
339 43% increase in likelihood of ADHD in the fully adjusted model, and a 55% increase in likelihood 
340 of ADHD in the sibling-matched analysis, when compared to non-exposure to preeclampsia or 
341 SGA. This may suggest that placental pathology may be a common factor increasing the 
342 likelihood of ADHD given the stronger association with preeclampsia/SGA than preeclampsia 
343 alone. 
344 Three, while preeclampsia was associated with ADHD, independent of gestational age, the 
345 likelihood of ADHD increases with decreasing gestational age. For example, preeclampsia was 
346 associated with a 7% increase in likelihood of ADHD when we restricted the analysis to those 
347 born ≥39 weeks’ gestation. However, the HR increases to 1.74 among those exposed to 
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349
350 This apparent preeclampsia-ADHD association may lack specificity however, as preeclampsia is 
351 associated with several neurodevelopmental outcomes such as autism spectrum disorder (ASD), 
352 cognitive impairment and intellectual disability (ID) in previous literature6. Therefore, 
353 preeclampsia could in fact be a risk factor for poor neurodevelopmental outcome in general, with 




358 The molecular basis of a preeclampsia-ADHD relationship remains unknown, and there are few 
359 studies that address the potential biological mechanisms of ADHD specifically. Animal models 
360 have shown that activation of interleukin-17a (IL-17a) in the fetal brain, in response to maternal 
361 immune activation, is associated with behavioural disturbances and an abnormal cortical 
362 phenotype in affected offspring26, 27. Therefore, we can speculate that maternal inflammation may 
363 be one such mechanism given the role of preeclampsia in chronic immune activation and elevated 
364 levels of inflammatory cytokines such as IL-17a26, 28, 29. In a separate study, maternal depressive 
365 symptoms throughout pregnancy were shown to be associated with ADHD in offspring30. As 
366 prenatal depression is linked to an increase in levels of pro-inflammatory cytokines31, it is possible 
367 that the inflammatory response observed in  preeclampsia may have a similar inflammatory 
368 mediated effect on ADHD-risk. 
369 However, it may also be possible that lifestyle factors not available in the registers, such as 
370 maternal alcohol consumption may also play a role. Alcohol consumption during pregnancy has 
371 been shown to affect placentation, fetal growth, and likelihood of ADHD32, 33. As preeclampsia is, 
372 at least in part, a disease of placentation, leaving the fetus vulnerable to the effects of placental 
373 pathology, particularly fetal growth restriction2, it is plausible that maternal alcohol consumption 
374 during pregnancy may contribute the observed preeclampsia-ADHD association. 
375
376 Strengths and Limitations
377 There are several strengths in this study. To our knowledge, it is the largest epidemiological study 
378 to examine the association between preeclampsia-ADHD to date. Use of National Registers 
379 minimised recall bias, while also allowed us to control for a wide range of confounding factors. In 
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381 shared by siblings such as family environment, diet, lifestyle factors, maternal characteristics, and 
382 genetic factors14. Furthermore, use of the E-value allowed us to quantify Bradford-Hill’s 
383 consideration of ‘strength of association’ in an attempt to investigate the robustness of our effect 
384 estimates to unmeasured confounding22. 
385 However, this study also contains several limitations. First, sibling-matched analysis may have 
386 reduced confounding due to shared genetic and familial factors. However, this method can only 
387 adjust for factors that are constant between pregnancies34 and the possibility of residual 
388 confounding cannot be ruled out in observational studies. Taking preeclampsia-ADHD as an 
389 example: (E-value for effect estimate = 1.51), an unmeasured confounder associated with both 
390 preeclampsia and ADHD by a risk-ratio of 1.51 may potentially explain away our preeclampsia-
391 ADHD effect estimate of 1.13. However, the effect-estimate for preeclampsia/SGA combined is 
392 less likely to be explained away by unmeasured confounding with an E-value of 2.47. 
393 Nonetheless, we cannot dismiss the potential effect of factors such as maternal alcohol 
394 consumption could have on findings.  Second, a lack of robust data on gestational hypertension 
395 limited our analysis to preeclampsia-ADHD only. Therefore, our comparison groups may contain 
396 women with a diagnosis of gestational hypertension, and while previous literature suggests a 
397 positive gestational hypertension-ADHD association35, this would likely bias our results towards 
398 to the null. Third, as outpatient data only started becoming available in 2001, more severe cases of 
399 ADHD may have been overrepresented in our data. However, when we restricted the study 
400 population to 2001-2010, results were not materially different from our main findings suggesting 
401 that the inclusion of less severe cases after 2001 may not have had a large impact on findings.
402 In conclusion, this population-based cohort suggests that preeclampsia as well as 
403 preeclampsia/SGA was associated with ADHD. Placental pathology may be a common 
404 mechanism increasing the likelihood of ADHD given the stronger association with 
405 preeclampsia/SGA, rather than preeclampsia alone. Further research is needed in order to clarify 
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Table 1: Perinatal and Sociodemographic Characteristics Related to Preeclampsia 
and Attention Deficit Hyperactivity Disorder Among Singleton Live Births in Sweden 
between 1990 and 2010
No. (%) of Infants
Characteristic Total Population Preeclampsia
Total Population 2047619 57493 (2.8)
ADHD 114934 (5.6) 3941 (6.9)
SGA 46719  (2.3) 7191 (12.6)
First-born child 879954  (42.9) 37642 (65.5)
Sex (male) 1052095 (51.4) 29938 (52.1)
Maternal age, years
<20 41285 (2.0) 1535  (2.7)
20-29 1015666 (49.6) 29354  (51.1)
30-39 935055 (45.7) 24569 (42.7)
≥40 55613 (2.7) 2035 (3.5)
Gestational age, weeks
<34 23538 (1.1) 5048 (8.8)
34 12181 (0.6) 1702  (3.0)
35 20845 (1.0) 2337 (4.1)
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37 98759 (4.8) 6385 (11.2)
38 277445 (13.6) 9153 (15.9)
39 472125  (23.1) 10632  (18.5)
40 580209  (28.4) 10128 (17.6)
>40 519037 (25.4) 8162 (14.2)
5-Minute Apgar score
0-3 (low) 3419 (0.2) 228 (0.4)
4-6 (intermediate) 15330  (0.8) 1251 (2.2)
7-10 (high) 2013115 (99.0) 55464 (97.4)
Mother’s country of birth
Sweden 1597528 (78.0) 47286 (82.2)
Other Nordic country 44704  (2.2) 1301 (2.3)
Other country 278978 (13.6) 5709  (9.9)
Missing 126409 (6.2) 3197 (5.6)
Father’s country of birth 
Sweden 1577672 (77.1) 46891 (81.6)
Other Nordic country 42429 (2.1) 1184 (2.0)
Other country 287522 (14.0) 5820 (10.1)
Missing 139996 (6.8) 3598 (6.3)
Maternal depression 
Never 1763485 (86.1) 49730 (86.5)
Previously diagnosed 157876 (7.7) 4574 (7.9)
Missing 126258 (6.2) 3189 (5.6)
Maternal bipolar disorder
Never 1904427 (93.0) 53772 (93.5)
Previously diagnosed 16934  (0.8) 532 (0.9)
Missing 126258 (6.2) 3189 (5.6)
Maternal nonaffective disorder
Never 1909156 (93.2) 53923 (93.8)
Previously diagnosed 12205 (0.6) 381 (0.6)
Missing 126258 (6.2) 3189 (5.6)
Paternal depression
Never 1831285  (89.4) 51886 (90.2)
Previously diagnosed 90076 (4.4) 2418 (4.2)
Missing 126258 (6.2) 3189 (5.6)
Paternal bipolar disorder
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Previously diagnosed 9907 (0.5) 246 (0.4)
Missing 126258 (6.2) 3189 (5.6)
Paternal nonaffective disorder
Never 1909156 (93.2) 53980  (93.9)
Previously diagnosed 12205 (0.6) 324 (0.5)
Missing 126258 (6.2) 3189 (5.6)
Income quintile
First 362540 (17.7) 8168  (14.2)
Second 383691 (18.7) 9542 (16.6)
Third 388138 (19.0) 11044 (19.2)
Fourth 390219 (19.1) 12509 (21.8)
Fifth 384890 (18.8) 12772 (22.2)
Missing 138141 (6.7) 3458 (6.0)
Smoking at first antenatal visit
No 1683882 (86.4) 49417 (90.7)
1-9 cigarettes/day 178176 (9.1) 3576 (6.5)
≥10 cigarettes/day 87699 (4.5) 1515 (2.8)
BMI at first antenatal visit
<20 172519 (8.4) 3048 (5.3)
20-24.9 868599 (42.4) 19449 (33.8)
25-29.9 372026 (18.2) 13037 (22.7)
≥30 154136 (7.5) 9415 (16.4)
Missing 480339 (23.5) 12544 (21.8)
Optimal gestational weight gain by 
BMI group at first antenatal visit36 
<20
Optimum 15910 (0.8) 211 (0.4)
Inadequate/Excessive 49130 (2.4) 891 (1.6)
20-24.9
Optimum 75448 (3.7) 1003 (1.7)
Inadequate/Excessive 254217 (12.4) 5855 (10.2)
25-29.9
Optimum 25752 (1.3) 527 (0.9)
Excessive 115893 (5.7) 4260 (7.4)
≥30
Optimum 12147 (0.6) 461 (0.8)
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Missing 1450882 (70.8) 41105 (71.5)
Highest parental level of education 
at child’s birthyear
Pre-high school 131210 (6.4) 3304 (5.7)
High school 886656 (43.3) 26603 (46.3)
Post high school 877980 (42.9) 23844 (41.5)
Missing 151773 (7.4) 3742 (6.5)
Categories were collapsed if cell count <10, for example, inadequate/excessive weight gain in women 
categorised as BMI<20 were combined for the purpose of displaying data only.
If missing data >5%, number (%) of missing data reported. 










This article is protected by copyright. All rights reserved
Table 2: Association between Preeclampsia and Attention Deficit Hyperactivity 
Disorder Among Singleton Live Births in Sweden between 1990 and 2010 










Preeclampsia 3941 1.22 (1.18, 1.26) 1.15 (1.12, 1.19) 1.13 (1.05, 1.22)
Preeclampsia and SGA¶ 582 1.49 (1.37, 1.61) 1.43 (1.31, 1.55) 1.55 (1.28, 1.88)
Preeclampsia without SGA 3322 1.19 (1.15, 1.23) 1.12 (1.08, 1.16) 1.09 (1.01, 1.18)
SGA without Preeclampsia 3205 1.51 (1.45, 1.56) 1.32 (1.27, 1.37) 1.29 (1.19, 1.39)
ADHD (ICD code and in receipt of medication) (n=80849)
Preeclampsia 2795 1.23 (1.18, 1.27) 1.16 (1.11, 1.20) 1.11 (1.02, 1.21)
Preeclampsia and SGA¶ 399 1.44 (1.31, 1.59) 1.37 (1.25, 1.52) 1.54 (1.23, 1.92)
Preeclampsia without SGA 2370 1.21 (1.16, 1.26) 1.13 (1.08, 1.18) 1.07 (0.98, 1.17)
ADHD (ICD code only) (n=94708)
Preeclampsia 3267 1.23 (1.18, 1.27) 1.16 (1.12, 1.20) 1.11 (1.03, 1.20)
Preeclampsia and SGA¶ 480 1.48 (1.35, 1.62) 1.41 (1.29, 1.55) 1.48 (1.21, 1.82)
Preeclampsia without SGA 2757 1.20 (1.16, 1.25) 1.13 (1.09, 1.18) 1.07 (0.99, 1.17)
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; SGA, small for gestational age; ICD, 
International Classification of Disease;
†Adjusted for year of birth.
‡Adjusted for year of birth, infant sex, maternal age, parental country of birth, parity, parental  depression, 
bipolar disorder, and non-affective psychiatric disorders, family income, maternal smoking status, BMI at first 
antenatal visit, gestational weight gain and parental level of education.
§Adjusted for same potential confounders as above with the exception of maternal country of birth.
¶Reference=no preeclampsia/no SGA.
Missing data on SGA for 37 cases of ADHD (full cohort). Missing data on SGA for 26 cases of ADHD (with 
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Table 3: Association between Preeclampsia and Attention Deficit Hyperactivity 










No Preeclampsia, ≥39 weeks’ gestational age (ref) 82844 1.00 1.00
Preeclampsia, ≥39 weeks’ gestational age 1808 1.14 (1.09, 1.20) 1.07 (1.02, 1.12)
No Preeclampsia, 37-38 weeks’ gestational age 21742 1.13 (1.12, 1.15) 1.09 (1.08, 1.11)
Preeclampsia, 37-38 weeks’ gestational age 1066 1.28 (1.20, 1.36) 1.20 (1.13, 1.28)
No Preeclampsia, 34-36 weeks’ gestational age 4545 1.28 (1.24, 1.32) 1.14 (1.11, 1.18)
Preeclampsia, 34-36 weeks’ gestational age 568 1.32 (1.22, 1.44) 1.24 (1.14, 1.35)
No Preeclampsia, <34 weeks’ gestational age 1703 1.78 (1.70, 1.87) 1.49 (1.42, 1.56)
Preeclampsia, <34 weeks’ gestational age 491 1.85 (1.69, 2.02) 1.74 (1.60, 1.91)
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; ref, reference; SGA, small for gestational 
age
†Adjusted for year of birth.
‡Adjusted for year of birth, infant sex, maternal age, parental country of birth, parity, parental  depression, 
bipolar disorder, and non-affective psychiatric disorders, family income, maternal smoking status, BMI at first 
antenatal visit, gestational weight gain and parental level of education.
Missing data on gestational age for 167 cases of ADHD. 
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